Replimune Group enters collaboration agreement with Roche

Replimune Group (REPL) announced that the company has entered into a Master Clinical Trial Collaboration and Supply Agreement in relation to Replimune’s RP2/3 program in colorectal cancer and hepatocellular carcinoma. Specifically, the companies will collaborate in third-line CRC and in first- and second-line HCC. Under the terms of the agreement, the companies will share costs and Roche (RHHBY) will supply its currently approved drugs, atezolizumab and bevacizumab for 2L HCC and 3L CRC combined with RP3. Roche will also supply atezolizumab and bevacizumab for 1L HCC combined with RP3, and for 3L CRC combined with RP2. Approximately 30 patients will be enrolled within each cohort. Replimune will have responsibility for operationalizing the clinical trial. Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in squamous cell carcinoma of the head and neck, hepatocellular carcinoma and colorectal cancer, combined with current standard of care where appropriate.